{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:08:45Z","timestamp":1793988525418,"version":"4.8.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophilia A is a chronic life-threatening condition caused by the deficiency or dysfunction of plasma coagulation factor VIII (FVIII) and commonly managed by prophylaxis with regular infusion of FVIII protein. A major obstacle to FVIII replacement therapy is the generation of alloantibodies that diminish efficacy. Disulfide bonds link pairs of cysteine residues in proteins and, in several proteins, have been found to be only partially formed in the mature proteins. FVIII contains 8 disulfide bonds and their redox state in human blood and recombinant FVIII was determined using differential cysteine alkylation and mass spectrometry. All 8 disulfide bonds were found to be unformed in \u223c10% to \u223c70% of molecules of FVIII populations, which suggested a conformational flexibility that could favor the binding of certain ligands to subsets of FVIII with more or less formed disulfide bonds. To test this hypothesis, the binding of a panel of 5 patient-derived anti-FVIII antibodies to the population of FVIII disulfide-bonded states was evaluated. All 5 antibodies bound preferentially to FVIII states in which 2 or 3 of the 8 disulfides are significantly more unformed: C1918-C1922 in the A3 domain, C2040-C2188 in the C1 domain, and C2193-C2345 in the C2 domain. Disulfide bond mutagenesis experiments and molecular dynamics simulations indicate that this subset of FVIII states has long-range conformational dynamism that favors antidrug antibody binding. These findings will assist efforts to engineer an FVIII molecule that is less prone to neutralization by antidrug antibodies and has general implications for autoimmune conditions and antibody drug efficacy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016474","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:03:46Z","timestamp":1744214626000},"page":"3706-3715","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Patient anti-FVIII drug antibodies bind preferentially to a subset of FVIII covalent states"],"prefix":"10.1182","volume":"9","author":[{"given":"Diego","family":"Butera","sequence":"first","affiliation":[{"name":"1School of Life Sciences, University of Technology Sydney and Centre for Cancer Innovations, Centenary Institute, The University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7441-4554","authenticated-orcid":false,"given":"Aster E.","family":"Pijning","sequence":"additional","affiliation":[{"name":"1School of Life Sciences, University of Technology Sydney and Centre for Cancer Innovations, Centenary Institute, The University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan G.","family":"Avery","sequence":"additional","affiliation":[{"name":"2Chemistry Department, Western Washington University, Bellingham, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8694-4894","authenticated-orcid":false,"given":"Carmen H.","family":"Coxon","sequence":"additional","affiliation":[{"name":"3Biotherapeutics and Advanced Therapies Team, MHRA SR&I South Mimms Laboratories, South Mimms, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7856-8574","authenticated-orcid":false,"given":"Clive","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"3Biotherapeutics and Advanced Therapies Team, MHRA SR&I South Mimms Laboratories, South Mimms, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Mimoun","sequence":"additional","affiliation":[{"name":"4INSERM, Centre de Recherche des Cordeliers, CNRS, Sorbonne Universit\u00e9, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5625-8447","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Lacroix-Desmazes","sequence":"additional","affiliation":[{"name":"4INSERM, Centre de Recherche des Cordeliers, CNRS, Sorbonne Universit\u00e9, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7982-5424","authenticated-orcid":false,"suffix":"Jr.","given":"Paul Clint","family":"Spiegel","sequence":"additional","affiliation":[{"name":"2Chemistry Department, Western Washington University, Bellingham, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6486-2863","authenticated-orcid":false,"given":"Philip J.","family":"Hogg","sequence":"additional","affiliation":[{"name":"1School of Life Sciences, University of Technology Sydney and Centre for Cancer Innovations, Centenary Institute, The University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"9","key":"2025081210013851400_bib2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","article-title":"Hemophilia A gene therapy: current and next-generation approaches","volume":"22","author":"Pipe","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"suppl 6","key":"2025081210013851400_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/hae.13507","article-title":"Bioengineered molecules for the management of haemophilia: promise and remaining challenges","volume":"24","author":"Pipe","year":"2018","journal-title":"Haemophilia"},{"issue":"3","key":"2025081210013851400_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13998","article-title":"Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres","volume":"26","author":"Soucie","year":"2020","journal-title":"Haemophilia"},{"issue":"8","key":"2025081210013851400_bib5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"issue":"7","key":"2025081210013851400_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/17474086.2020.1775576","article-title":"Prophylaxis for hemophilia A without inhibitors: treatment options and considerations","volume":"13","author":"Valentino","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"10274","key":"2025081210013851400_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2025081210013851400_bib8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MOH.0b013e328356ed37","article-title":"Inhibitory antibodies in hemophilia A","volume":"19","author":"Pratt","year":"2012","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"2025081210013851400_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3324\/haematol.2018.206383","article-title":"Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?","volume":"104","author":"Varthaman","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"2025081210013851400_bib10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1073\/pnas.47.9.1309","article-title":"The kinetics of formation of native ribonuclease during oxidation of the reduced polypeptide chain","volume":"47","author":"Anfinsen","year":"1961","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"2025081210013851400_bib11","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1021\/bi0603064","article-title":"Allosteric disulfide bonds","volume":"45","author":"Schmidt","year":"2006","journal-title":"Biochemistry"},{"issue":"4","key":"2025081210013851400_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0968-0004(03)00057-4","article-title":"Disulfide bonds as switches for protein function","volume":"28","author":"Hogg","year":"2003","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"2025081210013851400_bib13","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1074\/jbc.REV118.005604","article-title":"Allosteric disulfides: sophisticated molecular structures enabling flexible protein regulation","volume":"294","author":"Chiu","year":"2019","journal-title":"J Biol Chem"},{"issue":"7","key":"2025081210013851400_bib14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2016-04-636456","article-title":"Vascular thiol isomerases","volume":"128","author":"Flaumenhaft","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2025081210013851400_bib15","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/jth.15019","article-title":"Vascular thiol isomerases in thrombosis: the yin and yang","volume":"18","author":"Wu","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2025081210013851400_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/jth.15567","article-title":"Not one, but many forms of thrombosis proteins","volume":"20","author":"Pijning","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2025081210013851400_bib17","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1038\/s41467-020-19295-7","article-title":"Fibrinogen function achieved through multiple covalent states","volume":"11","author":"Butera","year":"2020","journal-title":"Nat Commun"},{"issue":"15","key":"2025081210013851400_bib18","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood.2021012441","article-title":"An alternate covalent form of platelet alphaIIbbeta3 integrin that resides in focal adhesions and has altered function","volume":"138","author":"Pijning","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2025081210013851400_bib19","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1182\/bloodadvances.2022008650","article-title":"Mechano-covalent protection of coagulation factor VIII by von Willebrand factor","volume":"7","author":"Butera","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"2025081210013851400_bib20","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.3390\/molecules25235729","article-title":"Multiple disulfide-bonded states of native proteins: estimate of number using probabilities of disulfide bond formation","volume":"25","author":"Hogg","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"2025081210013851400_bib21","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood.V97.4.966","article-title":"Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII","volume":"97","author":"van den Brink","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2025081210013851400_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.V95.1.156","article-title":"A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor","volume":"95","author":"Jacquemin","year":"2000","journal-title":"Blood"},{"issue":"2","key":"2025081210013851400_bib23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.V92.2.496","article-title":"Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor","volume":"92","author":"Jacquemin","year":"1998","journal-title":"Blood"},{"issue":"5","key":"2025081210013851400_bib24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/bjh.17227","article-title":"Characterisation and application of recombinant FVIII-neutralising antibodies from haemophilia A inhibitor patients","volume":"193","author":"Coxon","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2025081210013851400_bib25","doi-asserted-by":"crossref","first-page":"eaaq1477","DOI":"10.1126\/sciadv.aaq1477","article-title":"Autoregulation of von Willebrand factor function by a disulfide bond switch","volume":"4","author":"Butera","year":"2018","journal-title":"Sci Adv"},{"key":"2025081210013851400_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-1-4939-9187-7_4","article-title":"Quantification of the redox state of protein disulphide bonds","volume":"1967","author":"Chiu","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2025081210013851400_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jth.14621","article-title":"The 3.2 \u00c5 structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain","volume":"18","author":"Smith","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"21","key":"2025081210013851400_bib28","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood.2020009197","article-title":"Molecular determinants of the factor VIII\/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy","volume":"137","author":"Fuller","year":"2021","journal-title":"Blood"},{"key":"2025081210013851400_bib29","doi-asserted-by":"crossref","first-page":"697602","DOI":"10.3389\/fimmu.2021.697602","article-title":"Structure of blood coagulation factor VIII in complex with an anti-C2 domain non-classical, pathogenic antibody inhibitor","volume":"12","author":"Ronayne","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"2025081210013851400_bib30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bpj.2014.06.025","article-title":"Identification of allosteric disulfides from prestress analysis","volume":"107","author":"Zhou","year":"2014","journal-title":"Biophys J"},{"issue":"10","key":"2025081210013851400_bib31","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1111\/j.1538-7836.2010.03894.x","article-title":"Analysis of disulfide bonds in protein structures","volume":"8","author":"Wong","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"21","key":"2025081210013851400_bib32","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.2020008940","article-title":"Structure of blood coagulation factor VIII in complex with an anti-C1 domain pathogenic antibody inhibitor","volume":"137","author":"Gish","year":"2021","journal-title":"Blood"},{"key":"2025081210013851400_bib33","article-title":"Antibodies binding to the A2 domain of FVIII and inhibiting coagulation activity","author":"Jacquemin","year":"28  2010","journal-title":"US patent application US7858089B2"},{"issue":"11","key":"2025081210013851400_bib34","doi-asserted-by":"crossref","first-page":"9370","DOI":"10.1074\/jbc.M212053200","article-title":"Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII","volume":"278","author":"Bovenschen","year":"2003","journal-title":"J Biol Chem"},{"issue":"7","key":"2025081210013851400_bib35","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1182\/blood.V93.7.2267","article-title":"Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A","volume":"93","author":"Peerlinck","year":"1999","journal-title":"Blood"},{"issue":"16","key":"2025081210013851400_bib36","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2016-02-701805","article-title":"High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors","volume":"128","author":"Batsuli","year":"2016","journal-title":"Blood"},{"issue":"41","key":"2025081210013851400_bib37","doi-asserted-by":"crossref","first-page":"29670","DOI":"10.1074\/jbc.M113.473116","article-title":"Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake","volume":"288","author":"Bloem","year":"2013","journal-title":"J Biol Chem"},{"issue":"1","key":"2025081210013851400_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V98.1.13","article-title":"Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII","volume":"98","author":"Spiegel","year":"2001","journal-title":"Blood"},{"issue":"26","key":"2025081210013851400_bib39","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2013-08-519124","article-title":"Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2025081210013851400_bib40","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/jth.15793","article-title":"Structural insights into blood coagulation factor VIII: procoagulant complexes, membrane binding, and antibody inhibition","volume":"20","author":"Childers","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2025081210013851400_bib41","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1538-7836.2010.03878.x","article-title":"A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope","volume":"8","author":"Dimitrov","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2025081210013851400_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbagen.2005.05.010","article-title":"Selenocysteine in proteins-properties and biotechnological use","volume":"1726","author":"Johansson","year":"2005","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"2025081210013851400_bib43","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.4049\/jimmunol.169.5.2444","article-title":"Role of disulfide bonds in regulating antigen processing and epitope selection","volume":"169","author":"Li","year":"2002","journal-title":"J Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3706\/2403813\/blooda_adv-2025-016474-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3706\/2403813\/blooda_adv-2025-016474-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:14:23Z","timestamp":1755011663000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/15\/3706\/536666\/Patient-anti-FVIII-drug-antibodies-bind"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":42,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016474","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,12]]},"published":{"date-parts":[[2025,7,23]]}}}